Hanmi Fine Chemical, a key subsidiary of Hanmi Group specializing in active pharmaceutical ingredients (API), announced on May 19 that it has signed a contract with leading antibody-drug conjugate (ADC) company Rigakem BioScience to supply services related to ADC platform manufacturing. The company has also begun preparations for full-scale production.
Under this agreement, Hanmi Fine Chemical will produce core intermediates for Rigakem Bio’s proprietary ADC platform, ‘ConjuALL’. This partnership reflects Rigakem Bio’s strategic move to actively expand its presence in the ADC market, with the combined core technologies of both companies expected to generate significant synergy.
ADC is an innovative therapy that links an antibody with a cytotoxic payload via a linker, allowing targeted delivery of anti-cancer agents specifically to tumor cells. Rigakem Bio’s ‘ConjuALL’ platform is recognized as a next-generation ADC technology designed to overcome the limitations of existing platforms.
Hanmi Fine Chemical leverages advanced R&D capabilities, accumulated expertise, and a comprehensive quality management system aligned with global GMP standards. It possesses an integrated process for drug development and manufacturing, which has enabled it to strengthen collaborations with major domestic and international pharmaceutical and biotech firms continuously.
Through this contract, Hanmi Fine Chemical will provide CDMO services necessary for manufacturing key materials of the ADC platform.
Noyoung Su, Head of Hanmi's Onco Clinical Team, stated, “We are confident that our distinctive CDMO capabilities combined with Rigakem Bio’s innovative ADC technology will create unparalleled synergy. This partnership represents more than just a technological alliance; it is a strategic step toward securing a competitive edge in the ADC market and fostering new growth opportunities.”
